{"id":30972,"date":"2016-11-29T09:08:01","date_gmt":"2016-11-29T09:08:01","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=30972"},"modified":"2016-11-29T20:20:49","modified_gmt":"2016-11-29T20:20:49","slug":"factsheets-for-switching-to-rezolsta-darunavirc-or-evotaz-atazanavirc","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/30972","title":{"rendered":"Factsheets for switching to Rezolsta (darunavir\/c) or Evotaz (atazanavir\/c)"},"content":{"rendered":"<p><strong>Two new factsheets for doctors who are switching patients to coformulated cobicistat-boosted PIs.<\/strong><\/p>\n<p>Rezolsta (darunavir\/cobicistat) and Evotaz (atazanavir\/cobicistat) are new fixed dose combinations (FDC) combining the HIV protease inhibitors darunavir and atazanavir with the pharmacokinetic enhancer cobicistat. When switching from ritonavir-boosted darunavir or atazanavir to the respective FDCs there are multiple clinical differences that need to be considered for each patient.<\/p>\n<p>This resource has been jointly produced by the Royal Free London and Chelsea &amp; Westminster HIV teams and the University of Liverpool HIV pharmacology group.<\/p>\n<p><a href=\"http:\/\/www.bhiva.org\/patient-specific.aspx\">http:\/\/www.bhiva.org\/patient-specific.aspx<\/a><\/p>\n<p><a href=\"http:\/\/www.bhiva.org\/documents\/Publications\/patient-specific\/Resource-guide-to-switching-to-Rezolsta-or-Evotaz-UK.pdf\">http:\/\/www.bhiva.org\/documents\/Publications\/patient-specific\/Resource-guide-to-switching-to-Rezolsta-or-Evotaz-UK.pdf<\/a>\u00a0(PDF)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two new factsheets for doctors who are switching patients to coformulated cobicistat-boosted PIs. Rezolsta (darunavir\/cobicistat) and Evotaz (atazanavir\/cobicistat) are new fixed dose combinations (FDC) combining the HIV protease inhibitors darunavir and atazanavir with the pharmacokinetic enhancer cobicistat. When switching from &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-30972","post","type-post","status-publish","format-standard","hentry","category-guidelines"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=30972"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30972\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=30972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=30972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=30972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}